한글목차

자렐토는 혈전 치료 및 예방을 목적으로 하는 경구용 항응고제입니다. 아스피린과 병용하여 최근 증상이 있는 PAD로 인해 하지 혈전 재건술을 받은 환자를 포함한 성인 PAD 환자에서 주요 혈전성 혈관 사건(심근경색, 허혈성 뇌졸중, 급성 사지 허혈, 혈관에 의한 대단절)의 위험을 감소시키는데 적응증을 가지고 있습니다. 자렐토는 혈액 응고를 감소시키는 혈액 희석제(항응고제)이기 때문에 출혈을 유발할 수 있으며, 이는 심각한 사망을 초래할 수 있습니다. 따라서 이 약은 FDA로부터 경고 문구가 적힌 경고문이 붙어 있습니다.

자렐토는 관상동맥질환(CAD)과 PAD(LER 후 PAD 환자 포함) 모두에 적응증을 가진 최초이자 유일한 치료제입니다. 또한, 급성 사지 허혈이나 절단과 같은 심각한 혈전성 사건의 위험이 높은 PAD 환자에서 유의미한 효과를 입증한 20년간의 유일한 항응고제이기도 합니다.

Zalert는 FXa의 선택적 억제제이며, 활성에 보효소(항트롬빈 III 등)를 필요로 하지 않습니다. 리버록사반은 유리 FXa 및 프로트롬비나제 활성을 억제합니다. 리버록사반은 혈소판 응집에 직접 작용하지 않지만, FXa를 억제함으로써 FXa를 억제함으로써 트롬빈에 의해 유도된 혈소판 응집을 간접적으로 억제하여 트롬빈의 생성을 감소시킵니다.

앞으로 몇 년동안 말초동맥 질환(PAD) 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. PAD 치료제로서 자렐토의 우위에 영향을 미칠 수 있는 새로운 접근법에 초점을 맞춘 치료법을 개발하고 과제를 평가하고 기회를 모색하고 있으며, 다른 PAD 치료제들이 자렐토와 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 주자들이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다. 출시될 경우 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 말초동맥 질환(PAD) 치료제 자렐토(Zalert) 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 말초동맥 질환(PAD) 자렐토 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 자렐토 시장 평가

• PAD 자렐토 시장 전망
• 미국 및 일본 분석
  • 미국 및 일본의 PAD 치료제 자렐토 시장 규모
• 국가별 시장 분석
  • 미국
  • 일본

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"XARELTO Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about XARELTO for Peripheral Artery Disease (PAD) in the United States and Japan. A detailed picture of the XARELTO for PAD in the United States and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the XARELTO for PAD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XARELTO market forecast analysis for PAD in the US and Japan, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PAD.

Drug Summary:

XARELTO is an oral anticoagulant for the treatment and prevention of blood clots. In combination with aspirin, it is indicated to reduce the risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology) in adult patients with PAD, including patients who have recently undergone a lower extremity revascularization procedure due to symptomatic PAD. XARELTO can cause bleeding, which can be serious and may lead to death, as it is a blood thinner medicine (anticoagulant) that lowers blood clotting. Thus the drug has a boxed warning from FDA.

XARELTO is the first and only therapy indicated for both coronary artery disease (CAD) and PAD, including PAD patients post-LER. In addition, it is also the only anticoagulant in 20 years to show significant benefit in patients with PAD who remain at high risk for major thrombotic events, including acute limb ischemia and amputation.

• Dosage and administration

The recommended dose of XARELTO is 2.5 mg orally twice daily with or without food, in combination with aspirin (75-100 mg) once daily. No dose adjustment was needed for renal considerations.

• Mechanism of action

XARELTO is a selective inhibitor of FXa, and it does not require a cofactor (such as anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity; rivaroxaban does not directly affect platelet aggregation but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the XARELTO description, mechanism of action, dosage and administration, research and development activities in Peripheral Artery Disease (PAD).
• Elaborated details on XARELTO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the XARELTO research and development activities in PAD across the United States and Japan.
• The report also covers the patents information with expiry timeline around XARELTO.
• The report contains forecasted sales of XARELTO for PAD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for PAD.
• The report also features the SWOT analysis with analyst views for XARELTO in PAD.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XARELTO Analytical Perspective by DelveInsight

• In-depth XARELTO Market Assessment

This report provides a detailed market assessment of XARELTO for Peripheral Artery Disease (PAD) in the United States and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• XARELTO Clinical Assessment

The report provides the clinical trials information of XARELTO for PAD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Peripheral Artery Disease (PAD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XARELTO dominance.
• Other emerging products for PAD are expected to give tough market competition to XARELTO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XARELTO in PAD.
• Our in-depth analysis of the forecasted sales data of XARELTO from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XARELTO in PAD.

Key Questions:

• What is the product type, route of administration and mechanism of action of XARELTO?
• What is the clinical trial status of the study related to XARELTO in Peripheral Artery Disease (PAD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XARELTO development?
• What are the key designations that have been granted to XARELTO for PAD?
• What is the forecasted market scenario of XARELTO for PAD?
• What are the forecasted sales of XARELTO in the US and Japan?
• What are the other emerging products available and how are these giving competition to XARELTO for PAD?
• Which are the late-stage emerging therapies under development for the treatment of PAD?

Table of Contents

1. Report Introduction

2. XARELTO Overview in PAD

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. XARELTO Market Assessment

• 5.1. Market Outlook of XARELTO in PAD
• 5.2. The US and Japan Analysis
  • 5.2.1. Market Size of XARELTO in the US and Japan for PAD
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of XARELTO in the United States for PAD
  • 5.3.2. Market Size of XARELTO in Japan for PAD

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options